These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 19368958

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder.
    Diaz-Cano SJ, Blanes A, Rubio J, Matilla A, Wolfe HJ.
    Lab Invest; 2000 Mar; 80(3):279-89. PubMed ID: 10744064
    [Abstract] [Full Text] [Related]

  • 24. Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma.
    Mai KT, Elmontaser G, Perkins DG, Yazdi HM, Stinson WA, Thijssen A.
    BJU Int; 2004 Sep; 94(4):544-7. PubMed ID: 15329109
    [Abstract] [Full Text] [Related]

  • 25. Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ.
    Gaisa NT, Tilki D, Losen I, Dahl E, Stoehr R, Stief CG, Knüchel R.
    Hum Pathol; 2008 Aug; 39(8):1258-62. PubMed ID: 18547617
    [Abstract] [Full Text] [Related]

  • 26. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
    Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, Hartmann A, Stoehr R.
    Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
    [Abstract] [Full Text] [Related]

  • 27. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder.
    Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO.
    Cancer; 2004 Jul 01; 101(1):183-8. PubMed ID: 15222005
    [Abstract] [Full Text] [Related]

  • 28. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
    Bindels EM, Vermey M, van den Beemd R, Dinjens WN, Van Der Kwast TH.
    Cancer Res; 2000 Jan 01; 60(1):177-83. PubMed ID: 10646871
    [Abstract] [Full Text] [Related]

  • 29. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
    Yin M, Bastacky S, Parwani AV, McHale T, Dhir R.
    Hum Pathol; 2008 Apr 01; 39(4):527-35. PubMed ID: 18234280
    [Abstract] [Full Text] [Related]

  • 30. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
    Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG.
    Cancer Res; 2003 Dec 01; 63(23):8108-12. PubMed ID: 14678961
    [Abstract] [Full Text] [Related]

  • 31. Molecular evidence supporting field effect in urothelial carcinogenesis.
    Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, Cocco A, Cheng L.
    Clin Cancer Res; 2005 Sep 15; 11(18):6512-9. PubMed ID: 16166427
    [Abstract] [Full Text] [Related]

  • 32. Molecular pathways of urothelial development and bladder tumorigenesis.
    Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C.
    Urol Oncol; 2010 Sep 15; 28(4):401-8. PubMed ID: 20610278
    [Abstract] [Full Text] [Related]

  • 33. Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling.
    Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S, Wullich B, Bertz S, Weyerer V, Stoehr R, Breyer J, Burger M, Hartmann A, Strissel PL, Eckstein M.
    Cancer Res; 2021 Mar 15; 81(6):1552-1566. PubMed ID: 33472889
    [Abstract] [Full Text] [Related]

  • 34. Assessment of microsatellite instability in bladder and thyroid malignancies.
    Vaish M, Mishra SK, Mandhani A, Mittal RD, Mittal B.
    Teratog Carcinog Mutagen; 2003 Mar 15; Suppl 1():255-65. PubMed ID: 12616616
    [Abstract] [Full Text] [Related]

  • 35. [Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple urothelial carcinomas with mutator phenotype].
    Stöhr R, Catto JW, Azzouzi A, Rehmann I, Feeley K, Meuth M, Hamdy F, Burger M, Hartmann A.
    Verh Dtsch Ges Pathol; 2005 Mar 15; 89():225-33. PubMed ID: 18035696
    [Abstract] [Full Text] [Related]

  • 36. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma.
    Paner GP, Shen SS, Lapetino S, Venkataraman G, Barkan GA, Quek ML, Ro JY, Amin MB.
    Am J Surg Pathol; 2009 Jan 15; 33(1):91-8. PubMed ID: 18936687
    [Abstract] [Full Text] [Related]

  • 37. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia.
    Chaturvedi V, Li L, Hodges S, Johnston D, Ro JY, Logothetis C, von Eschenbach AC, Batsakis JG, Czerniak B.
    Oncogene; 1997 May 01; 14(17):2059-70. PubMed ID: 9160886
    [Abstract] [Full Text] [Related]

  • 38. [New WHO classification of urothelial carcinoma of the urinary bladder].
    Helpap B.
    Verh Dtsch Ges Pathol; 2002 May 01; 86():57-66. PubMed ID: 12647352
    [Abstract] [Full Text] [Related]

  • 39. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
    Kalantari MR, Ahmadnia H.
    Urol J; 2007 May 01; 4(4):230-3. PubMed ID: 18270948
    [Abstract] [Full Text] [Related]

  • 40. Significance of denuded urothelium in papillary urothelial lesions.
    Owens CL, Epstein JI.
    Am J Surg Pathol; 2007 Feb 01; 31(2):298-303. PubMed ID: 17255776
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.